
Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer
HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can negatively impact patients and their treatment. Now lessons learned from the HIV epidemic are helping people living with lung cancer and their loved ones.
During the first years of the HIV epidemic, some of the initial stigmatizing beliefs were that the virus only impacted men who have sex with men and that it was possible to contract it by sharing utensils or being in close confines with a person living with HIV. This helped contribute to acts of discrimination and an atmosphere of blame, and in some cases prevented people from getting diagnosed or seeking care.
People diagnosed with lung cancer face similar stigma challenges because of the known link to tobacco use – despite the National Cancer Institute's estimate that 10-20% of people with lung cancer in the United States are non-smokers. As with HIV, the blame and stigma surrounding this disease can decrease the likelihood that someone experiencing symptoms will seek care.
'Stigma isn't just a social issue; it's a public health crisis.' says Marcus Wilson, Gilead Senior Director, U.S. Public Affairs, HIV Advocacy. 'It determines the quality of care that people receive; whether they feel safe seeking care and, ultimately, their health outcomes.'
Gilead recently partnered with GRYT Health to host a New Lens on Lung Cancer workshop where people living with lung cancer and their loved ones shared their experience with stigma.
Rhonda Meckstroth's husband, Jeff, who had no history of tobacco use, was diagnosed with lung cancer in 2015. 'The first question was always, 'Is he a smoker?'' she says. 'We innately felt shame and guilt and would tell people he had been diagnosed with cancer, but we didn't want to say lung cancer.'
'People project their ideas of why you have lung cancer,' says Aurora Lucas, who was diagnosed at 28 years old. 'Within seconds they come up with absurd ideas.' She notes that some people speculated that it could be because she worked in a nail salon. Others incorrectly assumed it might be due to the building materials used in her childhood home in the Philippines.
As in the early days of the HIV epidemic, the lung cancer community quickly realized how important it is to advocate for themselves, both in and out of the clinic.
In Jeff's case, his care was in a rural health care system where doctors weren't always familiar with the latest research or the clinical trials available for lung cancer — or the fact that there are other risk factors besides tobacco use.
'Because Jeff didn't fit the criteria for lung cancer, his diagnosis was delayed for about six months,' says Rhonda. 'I quickly learned that instead of being angry when people asked me if Jeff had a history of tobacco use, I use it as a platform for education, and to put blame where it needs to be, which is on the tobacco industry.'
'We have so much to learn from the HIV community,' says Jeff Stibelman, who was diagnosed with lung cancer in 2021 after doctors also initially overlooked it on a scan he had done previously in 2017. 'I remember a billboard, it was of all people: old, young, black, white, Hispanic, Asian. All it said was: 'This is What HIV looks like.' That's what I want for our community.'
'Anyone with lungs can have lung cancer,' concludes Aurora. 'It's time to remove the blame.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hamilton Spectator
13 minutes ago
- Hamilton Spectator
Doctors, health experts call on N.S. to cover birth control and HIV-prevention drug
HALIFAX - Nova Scotia physicians and other sexual health experts are calling on the provincial government to fund birth control and increase access to a medication used to prevent HIV. Four doctors, the head of the Halifax Sexual Health Centre, and a pharmacy professor made the comments today at a legislature committee hearing in Halifax. Abbey Ferguson with the Halifax Sexual Health Centre says PrEP — an antiviral medication that prevents HIV transmission — is so expensive that many people who would benefit from the drug are not able to take it. The drug is estimated to cost between $200 and $250 per month. Dr. Melissa Brooks, the medical co-director of the Reproductive Options and Services Clinic, says the province's pharmacare plan is so restrictive that it often doesn't help those who cannot afford their preferred birth control option. Kari Ellen Graham, with Access Now Nova Scotia, urged the provincial government to sign on to the federal government's pharmacare program, which helps fund birth control. So far only P.E.I., Manitoba, British Columbia, and the Yukon have signed up to the federal pharmacare program. This report by The Canadian Press was first published June 10, 2025. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .

Epoch Times
an hour ago
- Epoch Times
The Best Father's Day Gift
After the nurse took my blood pressure and left the room, I waited alone for the arrival of my physician. At my age, this particular moment of an annual physical can bring some long thoughts. What if this was the visit where my doctor said, 'Well, Jeff, I'm afraid I have some bad news'? I began planning how I would tell my children and friends of my impending demise. As I paced the small room, I stopped by the magazine rack, where there were several copies of 'People' and even a 'New England Journal of Medicine.' There was also a Bible. As I opened it, my finger fell on Proverbs 17:6: 'Children's children are the crown of old men; and the glory of children are their fathers.'
Yahoo
2 hours ago
- Yahoo
US aid cuts threaten South Africa's status as powerhouse of HIV and tuberculosis research
South Africa risks losing its status as a powerhouse of HIV and tuberculosis research as sweeping American funding cuts jeopardise dozens of experimental trials. At least 27 HIV trials and another 20 TB trials in the country have been put at risk by Donald Trump's deep cuts to foreign assistance and global health spending, new analysis shows. Loss of the trials would hit research projects looking for new vaccines into both infections, as well as new long-lasting protective medicines and studies into the best way to treat children. Having intense HIV and TB epidemics as well as world class universities and research institutes has made South Africa a leader in combating the two diseases. Yet while the research has often been led by South African scientists, it has overwhelmingly been conducted with international funding, particularly with 20 years of generous United States government aid spending. Prof Salim Abdool Karim, director of the Centre for the Aids Program of Research in South Africa, said: 'The US is such a big player in our country – South Africa is a powerhouse in medical research because of what the US spends.' The bulk of funding for research came from the US National Institutes of Health (NIH), with the country receiving an estimated £111m ($150m) each year. Prof Ntobeko Ntusi, the president and chief executive of the South African Medical Research Council (SAMRC), said earlier this year: 'In many ways the South African health research landscape has been a victim of its own success, because for decades we have been the largest recipients of both [official development assistance] funding from the US for research [and] also the largest recipients of NIH funding outside of the US.' Now, unless alternative sources of money can be found, South African academic and research institutes could lose about 30 per cent of their annual income and may be forced to lay off hundreds of staff, the analysis found. 'There's been a huge dependence on US funding. The loss of it for South Africa means the cancellation of a huge amount of research,' said Tom Ellman, director of the MSF's Southern Africa Medical Unit (SAMU). The joint analysis by Treatment Action Group (TAG) and Doctors Without Borders (MSF) of NIH-funded research found 39 TB and HIV clinical research sites are under threat, placing at least 27 HIV trials and 20 TB trials at risk. The effect of cuts could be wider still, with research also funded through other US channels, including the US President's Emergency Plan for Aids Relief (Pepfar), which has been slashed by Donald Trump's administration. Lindsay McKenna, TB project co-director of TAG said: 'Public funding from the US government to South Africa is the scaffold on which pharmaceutical companies, philanthropies, and other governments invest in transformative TB and HIV science.' 'These ongoing funding disruptions by the US government don't just affect US-funded research projects, they put in peril a much wider ecosystem of global research.' Dr Ellman said a combination of the infections found in South Africa, its research base and its strong grass roots activism had combined, with US funding, to make the country so prominent in research. He said: 'For years, South Africa has spearheaded the research and development of critical innovative medical tools for the prevention, diagnosis, treatment and care of HIV and TB which have saved lives not just within South Africa's borders, but also in communities worldwide.' The country has more HIV patients than any other, with an estimated 8 million currently infected and 105,000 deaths annually. The high prevalence of HIV goes hand-in-hand with a high prevalence of tuberculosis, because TB takes advantage of patients' weakened immune systems. Tuberculosis is the biggest cause of death among those with HIV in South Africa, which recorded 54,000 TB deaths in 2023. At the same time, the country has strong research institutions and universities, and a history of medical innovation, including conducting the first heart transplant in 1969. Finally, the history of the apartheid struggle, and later the fight in the early 2000s to get antiretroviral drugs in the face of government AIDS denialism, has produced well-organised and politically-engaged health activists. According to the joint analysis, HIV trials now at risk include studies into using broadly neutralising antibodies (bNAbs) to find a cure, and also trials into long-lasting anti-HIV preventative jabs. The Brilliant Consortium, a collaboration of African researchers led by the SAMRC working to develop an HIV vaccine, lost all funding even as it was about to begin an early stage vaccine trial. Dr Ellman said: 'I think it would be a disaster if we gave up on the hope of finding an effective vaccine for HIV. All of that has been done with South Africa and without access to South African research and communities, it's not going to be possible.' The emergence of some resistance to antiretroviral drugs has also highlighted the importance of trials to find new drugs which can deal with the phenomenon. HIV trials are also looking at honing and improving existing treatment regimes, as well as simplifying and rolling out expensive techniques first used in the developing world. TB trials at risk include studies for new drugs and shorter, safer regimens for treatment and prevention. The cuts have a ripple effect beyond individual trials, because they also weaken research infrastructure which is used and relied on by other funders. That could have a knock-on effect on trials looking at new TB jab possibilities, including the promising new M72/AS01E vaccine candidate. South Africa is now scrabbling for alternative sources of funding to try to salvage as many of the research projects as possible. Dr Ellman said: 'We call on all potential donors to step up, as without sustained investment, we will never end these deadly epidemics.' Protect yourself and your family by learning more about Global Health Security Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.